Form 13-F position report

AMICUS THERAPEUTICS INC

Reported by ALLIANCEBERNSTEIN L P

FOLD CUSIP 03152W109 Manager CIK 0001109448

Reported 736,265 shares, up 54,420 (8.0%) from the prior quarter.

Reported value 22.5%; share count 8.0% vs. the prior quarter.

Added
% of reported 13F value < 0.01% This manager · Q2 2022
Shares 736,265 Quarter-end amount reported
Reported value $7,907,000 Fair value at quarter end
Consecutive quarters held 31 Through Q2 2022

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-12-31 8330000
2022-03-31 6457000
2022-06-30 7907000
2022-09-30 3286000
2022-12-31 3857493
2023-03-31 3503985
2023-06-30 4237480
2023-09-30 4102164
2023-12-31 4829552
2024-03-31 3797389
2024-06-30 3414752
2024-09-30 3943366
2024-12-31 3414081
2025-03-31 2957421
2025-06-30 2076718
2025-09-30 2855941
2025-12-31 38610948
2026-03-31 61463713
2026-06-30 0

Quarterly position history

How this manager's reported quarter-end position changed over time.

19 quarters
Quarterly reported position history for AMICUS THERAPEUTICS INC held by ALLIANCEBERNSTEIN L P.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q2 2026 Reduced 0 -4,316,272 (-100.0%) 0 $0 2026-08-14
Q1 2026 Added 4,316,272 +1,604,829 (59.2%) 0.02% $61,463,713 2026-05-15
Q4 2025 Added 2,711,443 +2,349,014 (648.1%) 0.01% $38,610,948 2026-02-17
Q3 2025 Unchanged 362,429 0 (0.0%) < 0.01% $2,855,941 2025-11-14
Q2 2025 Unchanged 362,429 0 (0.0%) < 0.01% $2,076,718 2025-08-14
Q1 2025 Unchanged 362,429 0 (0.0%) < 0.01% $2,957,421 2025-05-15
Q4 2024 Reduced 362,429 -6,800 (-1.8%) < 0.01% $3,414,081 2025-02-12
Q3 2024 Added 369,229 +25,000 (7.3%) < 0.01% $3,943,366 2024-11-14
Q2 2024 Added 344,229 +21,870 (6.8%) < 0.01% $3,414,752 2024-08-14
Q1 2024 Reduced 322,359 -17,990 (-5.3%) < 0.01% $3,797,389 2024-05-14
Q4 2023 Added 340,349 +3,000 (0.9%) < 0.01% $4,829,552 2024-02-14
Q3 2023 Reduced 337,349 -30 (0.0%) < 0.01% $4,102,164 2023-11-14
Q2 2023 Added 337,379 +21,420 (6.8%) < 0.01% $4,237,480 2023-08-15
Q1 2023 Added 315,959 +30 (0.0%) < 0.01% $3,503,985 2023-05-15
Q4 2022 Added 315,929 +1,200 (0.4%) < 0.01% $3,857,493 2023-02-15
Q3 2022 Reduced 314,729 -421,536 (-57.3%) < 0.01% $3,286,000 2022-11-15
Q2 2022 Added 736,265 +54,420 (8.0%) < 0.01% $7,907,000 2022-08-15
Q1 2022 Reduced 681,845 -39,380 (-5.5%) < 0.01% $6,457,000 2022-05-13
Q4 2021 Reduced 721,225 -17,423 (-2.4%) < 0.01% $8,330,000 2022-02-14
Five years are shown. A free account unlocks the complete reported history. Unlock full history

Who else reported the position

230 managers reported AMICUS THERAPEUTICS INC for Q2 2022.

Managers reporting AMICUS THERAPEUTICS INC in Q2 2022.
Manager Activity Shares Change % of reported 13F Reported value Tenure
PERCEPTIVE ADVISORS LLC Reduced 26,895,532 -660,313 9.05% $288,858,000 34 qtrs
Avoro Capital Advisors LLC Added 26,800,000 +6,300,000 5.69% $287,832,000 31 qtrs
VANGUARD GROUP INC Added 25,732,089 +74,919 < 0.01% $276,363,000 37 qtrs
Redmile Group LLC Reduced 22,158,891 -170,495 9.09% $237,986,000 37 qtrs
BlackRock Inc Added 20,249,858 +656,857 < 0.01% $217,484,000 29 qtrs
MORGAN STANLEY Added 18,313,444 +1,092,228 0.03% $196,686,000 37 qtrs
JANUS HENDERSON GROUP PLC Added 16,780,141 +1,157,528 0.12% $180,236,000 21 qtrs
JPMorgan Chase & Co Added 15,864,107 +312,434 0.02% $170,381,000 30 qtrs
STATE STREET CORPORATION Added 13,918,315 +1,983,752 < 0.01% $149,483,000 37 qtrs
WELLINGTON MANAGEMENT GROUP LLP Reduced 11,024,744 -15,594,363 0.02% $118,405,000 29 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
June 30, 2022
Filed
August 15, 2022
Filing type
13F-HR
Position type
COM

Voting authority reported

Sole
645,133
Shared
0
None
91,132

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.